Luciferase Reporter Cell Line - MUM-2B

MUM-2B is a highly invasive human uveal melanoma (UM) cell line, originally established from a heterogeneous tumor deposit that had metastasized from the eye to the liver. Characterized by its epithelioid morphology, MUM-2B is particularly notable for its interconverted phenotype—expressing both epithelial and mesenchymal traits—and its unique capacity for vasculogenic mimicry, allowing the aggressive tumor cells to form their own microvascular, fluid-conducting networks. The Luciferase Reporter Cell Line - MUM-2B advances this advanced melanoma model through the stable integration of the firefly luciferase gene into the cellular genome. This precise genetic engineering enables the cells to constitutively express the luciferase enzyme, generating a highly robust and quantifiable bioluminescent signal upon exposure to the substrate D-luciferin. Crucially, the introduction of the reporter gene is carefully designed to preserve the foundational biological integrity of the parental cells. The engineered cells maintain their high metastatic potential, characteristic morphological traits, and aggressive molecular signature, ensuring a biologically authentic model for studying advanced ocular cancers.

The functional addition of the luciferase reporter makes this MUM-2B cell line an invaluable asset for both in vitro analytics and complex in vivo preclinical modeling. In the laboratory, the steady bioluminescent output provides a highly sensitive, continuous metric for quantifying cell proliferation, monitoring viability, and conducting high-throughput screening of novel chemotherapeutics or inhibitors designed to target vasculogenic mimicry. The most significant advantage of this cell line, however, is demonstrated in preclinical animal research. Because uveal melanoma has a profound clinical tendency to metastasize selectively to the liver, orthotopic (intraocular) or systemic implantation of the MUM-2B luciferase cells into immunodeficient mice allows for the creation of highly accurate metastatic xenograft models. The robust bioluminescent signal facilitates highly sensitive, non-invasive longitudinal imaging in living subjects. This enables researchers to visually map primary intraocular tumor growth, precisely track systemic dissemination to the liver, and dynamically evaluate the efficacy of experimental targeted therapies over extended timelines without the need for destructive endpoint analyses.